Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02656043 | A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel | PHASE1 | COMPLETED | 213 | — | — | Sep 17, 2015 | Mar 17, 2017 | Jan 22, 2019 | 20 | Canada |
| Arm | Type | Description |
|---|---|---|
| XPF-005 | ACTIVE_COMPARATOR | Active treatment: XPF-005 Gel |
| Vehicle gel | PLACEBO_COMPARATOR | Placebo: XPF-005 Vehicle Gel |
| Name | Type | Description |
|---|---|---|
| XPF-005 | DRUG | Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris. |
| Placebo | DRUG | - |
Key Inclusion Criteria: 1. Aged between 18 and 50, inclusive 2. Male or female, agree to comply with contraceptive requirements 3. Signed Informed Consent Form 4. Clinical diagnosis of facial acne vulgaris defined as: * 25 to 75 inflammatory lesions, * 20 to 120 non-inflammatory lesions, and...